AbbVie taps Jennifer Doudna startup for licensing deal worth up to $300M for 2 'off-the-shelf' CRISPR-edited CAR-Ts
“Off-the-shelf” CAR-Ts have emerged as a hot-ticket target in next-gen oncology R&D, with Big Pharmas placing big down payments on novel tech. Now, a California biotech player founded by one of the CRISPR movement’s most prominent mouthpieces has added major drugmaker AbbVie as a teammate.
AbbVie will pay Caribou Biosciences $40 million in upfront cash and $300 million in biobucks to develop two of the biotech’s allogeneic CAR-T therapies, the partners said Wednesday. The biotech will also be due royalty payments for any future commercial assets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.